Drug interactions between bicalutamide and tamoxifen
Interactions between your drugs
tamoxifen ↔ bicalutamide
Applies to:tamoxifen and bicalutamide
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In a single, active-controlled, clinical study comparing abarelix to LHRH (luteinizing hormone releasing hormone) agonist plus nonsteroidal antiandrogen therapy, both therapies were found to prolong the mean Fridericia-corrected QT interval (QTcF) by more than 10 msec from baseline. In approximately 20% of patients in both groups, there were either changes from baseline QTc of greater than 30 msec or end-of-treatment QTc values exceeding 450 msec. Similar results were observed in two other Phase 3 studies with abarelix and the active-control treatments. In a randomized, active-controlled trial comparing degarelix to leuprolide, three patients (<1%) in the pooled degarelix group and four patients (2%) in the leuprolide 7.5 mg group had a QTcF of 500 ms or greater. From baseline to end of study, the median change was 12.3 msec for degarelix and 16.7 msec for leuprolide. Investigators believe that long-term androgen deprivation is responsible for these changes, as testosterone has been found to shorten ventricular repolarization. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).
MANAGEMENT: The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.
- "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.
- "Product Information. Zoladex (goserelin)." Zeneca Pharmaceuticals, Wilmington, DE.
- "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals, New York, NY.
- "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc, Tarrytown, NY.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Trelstar (triptorelin)" Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc, Waltham, MA.
- "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc, Deerfield, IL.
Drug and food interactions
Applies to: tamoxifen
Talk to your doctor before using tamoxifen with soy products. There is some evidence that substances present in soy may stimulate breast tumor growth and interfere with the action of tamoxifen, although this has not been proven. Whether soy products are effective for hot flashes is also uncertain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
The recommended maximum number of medicines in the 'antineoplastic hormones' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'antineoplastic hormones' category:
Drug Interaction Classification
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.